



UNITED STATES PATENT AND TRADEMARK OFFICE

#12/Amndt  
4/19  
RECEIVED  
APR 17 2002  
TECH CENTER 1600/2900

In re application of :  
E. Raspe *et al.* : Examiner: S. Chunduru  
Serial No.: 09/646,924 : Group Art Unit: 1656  
Filed: September 25, 2000 :

For: **USE OF ROR RECEPTORS FOR SCREENING SUBSTANCES USEFUL  
FOR THE TREATMENT OF ATHEROSCLEROSIS**

AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

I hereby certify that this correspondence is being  
deposited with the U.S. Postal Services as First Class  
Mail in an envelope addressed to:  
Assistant Commissioner For Patents.  
Washington, D.C. 20231 on: 4/11/02  
Name: Jo Ann P. Hughes  
Signature: Jo Ann P. Hughes  
Date: 4/11/02

Sir:

In response to the Office Action of November 1, 2001, please amend the above-identified  
application as follows:

IN THE CLAIMS:

Please **amend** claims 1, 3, 4, 7, 8, 16 and 22 as follows:

1. (Twice Amended) A method of screening a substance for usefulness in the treatment of  
a lipid metabolism dysfunction comprising contacting said substance with a ROR receptor, or a  
response element thereof involved in the regulation of the apo C-III gene, and measuring the level of  
apo C-III gene expression.

3. (Twice Amended) A method of screening a substance for usefulness in the treatment of  
a lipid metabolism dysfunction, comprising contacting said substance with (a) a receptor of the ROR  
family involved in the regulation of the expression of the apo C-III gene, (b) a response element of the  
ROR receptor, or (c) a nuclear factor which functionally couples ROR to a RNA polymerase  
complex, and then measuring: